BACKGROUND: The approval of new therapies for metastatic castration-resistant @entity263 (mCRPC), including the oral agents @entity15512 and @entity14164 , has altered the standard of care for @entity1 with mCRPC. Little information exists regarding the sequences in which new therapies for mCRPC with evidence of survival benefits are used. OBJECTIVE: To describe the sequence of medication use for @entity1 with mCRPC as observed in 3 healthcare data sets. METHODS: Three healthcare claims data sets were used to identify @entity1 with mCRPC who had no previous use of and were newly initiating 1 of the 2 oral study drugs (ie, @entity15512 or @entity14164 ). The index date was the first study drug claim after September 1, 2012. @entity1 were followed until the data cutoff or until being lost to follow-up. Descriptive statistics summarized the proportion of @entity1 receiving 1 line of therapy versus >= 2 lines of therapy. The use of a @entity228 and the mean monthly pharmacy costs of @entity15512 or @entity14164 during the follow-up period were compared between the cohorts. RESULTS: A total of 3525 @entity1 with mCRPC were identified from data set 1, 499 @entity1 from data set 2, and 1949 @entity1 from data set 3. The first-line use of @entity15512 was observed in 74%, 82%, and 80% of data sets 1, 2, and 3, respectively, and the first-line use of @entity14164 was seen in 26%, 18%, and 20%, respectively, of these same populations. The concomitant use of @entity288 was observed in @entity1 receiving first-line @entity15512 and in @entity1 receiving first-line @entity14164 in all 3 data sets. After September 2012, @entity15512 was the most frequently administered therapy for mCRPC among the 2 oral agents, @entity15512 and @entity14164 . The monthly pharmacy costs associated with @entity15512 were significantly lower than those associated with @entity14164 in all 3 data sets. CONCLUSIONS: Based on the data used in this study, @entity15512 was more frequently administered for @entity1 with mCRPC than @entity14164 . The concomitant use of corticosteroids was common in @entity1 receiving first-line @entity15512 or first-line @entity14164 therapy. @entity1 receiving @entity15512 had significantly lower monthly pharmacy costs than @entity1 receiving @entity14164 . These findings may facilitate the estimation of the budgetary impact of a treatment mix for population health and for managed care stakeholders.

Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity15512 :: ('MESH:C089742', 'Chemical') :: ['abiraterone acetate'] @entity14164 :: ('MESH:C540278', 'Chemical') :: ['enzalutamide'] @entity228 :: ('CHEBI:50858', 'Chemical') :: ['corticosteroid'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']
@entity263 :: (MESH:D011471,Disease) :: ['Prostate Cancer']
